Lower Alzheimer Risk Seen With PDE5i Initiation for Erectile Dysfunction

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 7, 2024 -- For men with erectile dysfunction (ED), phosphodiesterase type 5 inhibitor (PDE5i) initiation is associated with a lower risk for Alzheimer disease (AD), according to a study published online Feb. 7 in Neurology.

Matthew Adesuyan, from the UCL School of Pharmacy in London, and colleagues conducted a cohort study involving men aged 40 years and older with a new diagnosis of ED between 2000 and 2017 to examine the association between PDE5i initiation compared to nonuse and the risk for developing AD.

The study included 269,725 men; during a median follow-up of 5.1 years, 1,119 were newly diagnosed with AD. The researchers found that the adjusted hazard ratio for AD was 0.82 for PDE5i initiators compared with nonuse. Individuals issued >20 prescriptions had a reduced risk for AD (hazard ratios, 0.56 and 0.65 for 21 to 50 and >50 prescriptions, respectively). The primary findings were supported in a sensitivity analysis with a one-year lag period (hazard ratio, 0.82), but were not significant with inclusion of a three-year lag period.

"The findings of this large population-based study suggest that the use of PDE5i may be associated with a reduced risk of incident AD," the authors write. "The greatest risk reduction was observed in those issued >20 prescriptions over a median follow-up of five years."

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-02-08 22:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords